Menu Search
Equities

Swedish Orphan Biovitrum AB (publ)

SOBI:STO

Swedish Orphan Biovitrum AB (publ)

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (SEK)290.00
  • Today's Change-0.600 / -0.21%
  • Shares traded708.73k
  • 1 Year change+20.23%
  • Beta0.1581
Data delayed at least 15 minutes, as of Nov 22 2024 17:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in SEKIncome statement in SEKView more

Year on year Swedish Orphan Biovitrum AB (publ) had net income fall -8.72% from 2.64bn to 2.41bn despite a 17.74% increase in revenues from 18.79bn to 22.12bn.
Gross margin78.60%
Net profit margin13.81%
Operating margin21.91%
Return on assets4.75%
Return on equity9.83%
Return on investment5.85%
More ▼

Cash flow in SEKView more

In 2023, cash reserves at Swedish Orphan Biovitrum AB (publ) fell by 457.00m. Cash Flow from Financing totalled 17.01bn or 76.90% of revenues. In addition the company generated 4.47bn in cash from operations while cash used for investing totalled 21.90bn.
Cash flow per share20.65
Price/Cash flow per share14.37
Book value per share108.01
Tangible book value per share-60.52
More ▼

Balance sheet in SEKView more

Swedish Orphan Biovitrum AB (publ) has a Debt to Total Capital ratio of 32.50%, a lower figure than the previous year's 51.34%.
Current ratio0.9098
Quick ratio0.6225
Total debt/total equity0.4817
Total debt/total capital0.325
More ▼

Growth rates in SEK

Year on year, growth in earnings per share excluding extraordinary items dropped -12.47%. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
EPS growth(5 years)-2.84
EPS (TTM) vs
TTM 1 year ago		13.85
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.